Stacey Titus • May 10, 2024
In-Person Bighearted Warriors Unite featuring The Christ Hospital & Cincinnati Children’s

The In-Person Bighearted Warriors Unite featuring The Christ Hospital & Cincinnati Children’s event held in Cincinnati, Ohio was a tremendous success, where we were pleased to see so many of you in person. The event commenced with a warm welcome address by Lisa Salberg. The day was focused on educating people about HCM, and it was led by HCM Program Directors Dr. Wojciech Mazur and Dr. Ankit Bhatia. The event featured a group of distinguished speakers, including Dr. Edward Schloss, Dr. Puvi Seshiah, Courtney Hannum, Cassady Palmer, Dr. Ryan Moore, Dr. Tom Ryan, and the Anderson & Steel Family. The HCMA would like to thank all of the staff and volunteers who worked tirelessly to make this day successful and impactful for the HCM community. Lastly, Brittany Johnson of The Christ Hospital took some beautiful photos that captured the essence of the event and are available for viewing.

We are looking forward to the next in-person event. Stay tuned for more!

HCMA Blog

Pro Publica Releases Results of FDA Investigation

By Erica Friedman • June 26, 2025
Investigative journalists Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang from Pro Publica and NPR have concluded a 14-month long investigation into the quality of generic drugs coming into the United States from overseas. Among the many voices that spoke up for American patients was HCMA Founder and CEO, Lisa Salberg who has felt the effects of low-quality drugs personally. Salberg believes that fixing this problem is something we can do, even in this time, when even health care is highly politicized. Read the key takeaways from ProPublica’s 14-month investigation into the FDA’s oversight of foreign drugmakers in Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs .
A light blue and dark blue paintbrush stroke intersect to make a stylized

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran) for Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
More Posts